EA017668B1 - Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов - Google Patents

Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов Download PDF

Info

Publication number
EA017668B1
EA017668B1 EA201070762A EA201070762A EA017668B1 EA 017668 B1 EA017668 B1 EA 017668B1 EA 201070762 A EA201070762 A EA 201070762A EA 201070762 A EA201070762 A EA 201070762A EA 017668 B1 EA017668 B1 EA 017668B1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
mol
formula
hours
dibenzo
Prior art date
Application number
EA201070762A
Other languages
English (en)
Russian (ru)
Other versions
EA201070762A1 (ru
Inventor
Константинос Гавардинас
Прабхакар Кондаджи Джадхав
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA017668(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201070762A1 publication Critical patent/EA201070762A1/ru
Publication of EA017668B1 publication Critical patent/EA017668B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
EA201070762A 2007-12-19 2008-12-09 Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов EA017668B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19
PCT/US2008/085997 WO2009085584A1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Publications (2)

Publication Number Publication Date
EA201070762A1 EA201070762A1 (ru) 2010-12-30
EA017668B1 true EA017668B1 (ru) 2013-02-28

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070762A EA017668B1 (ru) 2007-12-19 2008-12-09 Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов

Country Status (33)

Country Link
US (1) US7994164B2 (https=)
EP (2) EP2235007B1 (https=)
JP (1) JP5562866B2 (https=)
KR (1) KR101254382B1 (https=)
CN (1) CN101903377B (https=)
AR (1) AR069554A1 (https=)
AU (1) AU2008343524B2 (https=)
BR (1) BRPI0820805A2 (https=)
CA (1) CA2710409C (https=)
CL (1) CL2008003600A1 (https=)
CO (1) CO6300953A2 (https=)
DK (1) DK2235007T3 (https=)
DO (1) DOP2010000185A (https=)
EA (1) EA017668B1 (https=)
EC (2) ECSP10010266A (https=)
ES (2) ES2396605T3 (https=)
GT (1) GT201000179A (https=)
HR (1) HRP20120916T1 (https=)
IL (1) IL206353A (https=)
MA (1) MA31910B1 (https=)
MX (1) MX2010006911A (https=)
MY (1) MY150474A (https=)
NZ (1) NZ586300A (https=)
PE (1) PE20091057A1 (https=)
PL (1) PL2235007T3 (https=)
PT (1) PT2235007E (https=)
RS (1) RS52594B (https=)
SI (1) SI2235007T1 (https=)
TN (1) TN2010000292A1 (https=)
TW (1) TWI431010B (https=)
UA (1) UA100131C2 (https=)
WO (1) WO2009085584A1 (https=)
ZA (1) ZA201004257B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693997C (en) 2007-08-03 2013-01-15 Pierre L. Beaulieu Viral polymerase inhibitors
CN101903351B (zh) 2007-12-19 2014-09-10 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
WO2010104721A1 (en) * 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
ES2566934T3 (es) 2010-05-10 2016-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
EA027936B1 (ru) 2013-05-02 2017-09-29 Пфайзер Инк. Производные имидазотриазина в качестве ингибиторов фосфодиэстеразы 10 (pde10)
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
EP3160948B1 (en) 2014-06-30 2018-10-24 Astrazeneca AB Benzoxazinone amides as mineralocorticoid receptor modulators
NZ730759A (en) * 2014-11-21 2018-10-26 Lilly Co Eli 1,2-benzothiazole compounds for the treatment of kidney disorders
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
CR20240015A (es) * 2016-09-24 2024-04-05 Novo Nordisk As COMPOSICIÓN FARMACÉUTICA CON ANTAGONISTA DEL RECEPTOR DE MINERALOCORTICOIDES Y SU USO (Divisional Expediente 2019-203)
JP7697961B2 (ja) 2020-03-11 2025-06-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345747A2 (en) * 1988-06-09 1989-12-13 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
FR2603713B1 (fr) 1986-09-10 1992-07-24 Canon Kk Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant
GB8914061D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US6372779B1 (en) 1997-12-29 2002-04-16 Ortho Pharmaceutical Corporation Anti-inflammatory compounds
EP1154997A4 (en) 1999-01-26 2002-11-04 Dana Farber Cancer Inst Inc PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE
CN1911930A (zh) * 2001-11-21 2007-02-14 千禧药品公司 趋化因子受体拮抗剂及其方法和用途
CN1918151A (zh) 2003-12-19 2007-02-21 伊莱利利公司 三环甾类激素核受体调节剂
US7482344B2 (en) 2003-12-19 2009-01-27 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
US20090054417A1 (en) * 2004-07-28 2009-02-26 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
ES2547724T3 (es) 2004-11-10 2015-10-08 Incyte Corporation Compuestos de lactama y su uso como productos farmacéuticos
DK2089367T3 (da) 2006-10-31 2012-02-06 Pfizer Prod Inc Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
EP2142194A1 (en) 2007-03-29 2010-01-13 N.V. Organon Mineralocorticoid receptor antagonists
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
EP2252615A1 (en) 2008-01-25 2010-11-24 Arena Pharmaceuticals, Inc. Dihydro- 1h- pyrrolo [1,2-a]indol-1-yl carboxylic derivatives which act as s1p1 agonists
WO2010104721A1 (en) 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345747A2 (en) * 1988-06-09 1989-12-13 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators

Also Published As

Publication number Publication date
MA31910B1 (fr) 2010-12-01
JP5562866B2 (ja) 2014-07-30
IL206353A (en) 2014-06-30
ECSP12012048A (es) 2012-08-31
EP2537845B1 (en) 2014-03-19
DK2235007T3 (da) 2012-12-17
KR101254382B1 (ko) 2013-04-15
AU2008343524B2 (en) 2012-03-08
EP2235007A1 (en) 2010-10-06
AR069554A1 (es) 2010-02-03
MX2010006911A (es) 2010-10-05
MY150474A (en) 2014-01-30
PL2235007T3 (pl) 2013-03-29
CO6300953A2 (es) 2011-07-21
DOP2010000185A (es) 2010-09-15
SI2235007T1 (sl) 2013-01-31
CL2008003600A1 (es) 2010-02-19
JP2011507868A (ja) 2011-03-10
TW200930721A (en) 2009-07-16
CA2710409C (en) 2012-11-06
KR20100082866A (ko) 2010-07-20
WO2009085584A1 (en) 2009-07-09
NZ586300A (en) 2012-06-29
HK1144284A1 (en) 2011-02-11
EP2537845A1 (en) 2012-12-26
IL206353A0 (en) 2010-12-30
ES2459318T3 (es) 2014-05-09
ECSP10010266A (es) 2010-07-30
HRP20120916T1 (hr) 2012-12-31
TWI431010B (zh) 2014-03-21
EP2235007B1 (en) 2012-10-31
ZA201004257B (en) 2011-11-30
AU2008343524A1 (en) 2009-07-09
CA2710409A1 (en) 2009-07-09
US7994164B2 (en) 2011-08-09
RS52594B (sr) 2013-04-30
CN101903377A (zh) 2010-12-01
TN2010000292A1 (en) 2011-11-11
PE20091057A1 (es) 2009-07-20
BRPI0820805A2 (pt) 2015-06-16
EA201070762A1 (ru) 2010-12-30
GT201000179A (es) 2012-04-16
CN101903377B (zh) 2014-07-09
PT2235007E (pt) 2013-01-22
UA100131C2 (uk) 2012-11-26
ES2396605T3 (es) 2013-02-22
US20090163472A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
EA017668B1 (ru) Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов
JP6908536B2 (ja) ムスカリンｍ２受容体の正のアロステリックモジュレーター
EP4647433A1 (en) Shp2 inhibitor and uses thereof
BR112020026653A2 (pt) Compostos heterocíclicos como inibidores de trk
TW202400608A (zh) 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
CN111479813A (zh) 作为加压素v1a受体拮抗剂的三唑并苯并吖庚因
EA029311B1 (ru) Hантагонисты, имеющие феноксипиперидиновое ядро в структуре, и их применение для лечения и/или профилактики состояний, опосредуемых hрецепторами
CN109689656B (zh) 7-取代的1-芳基二氮杂萘-3-羧酰胺及其用途
TW202417458A (zh) 調節her2的化合物及方法
TW202204343A (zh) 經取代之３－苯氧基氮雜環丁烷－１－基－吡
US20250177539A1 (en) Er degraders and uses thereof
HK1144284B (en) 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists
WO2025122809A1 (en) M4 positive allosteric modulators
WO2026039512A1 (en) Kras inhibitors
TW202430523A (zh) pan-KRAS降解劑及其製備方法與應用
TW202610655A (zh) Kras抑制劑

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KG MD TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ TJ RU